ClinicalTrials.gg
RecruitingNCT07645118IMPERIAUpdated Nov 19, 2026

Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal Cancer

A Phase 2 interventional study of Nivolumab and HDRBET in Locally Advanced Rectal Cancer, sponsored by Dr. Te Vuong. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Dr. Te Vuong · Phase 2, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 28, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies testing nivolumab in Rectal Neoplasms — 2 open to participants now, 10 under way, none of them phase 3. Nivolumab · Rectal Neoplasms.

Planned enrollment
13th of 14
10 · median 40
Started
2026
the only one that year
Phase 2
10 of 14
2 open now
Registered
14th of 14
by date
Lead sponsor
1 of 14
Dr. Te Vuong

Among the 14 studies testing nivolumab in Rectal Neoplasms, this one is the 13th largest by planned enrollment, is the only one that started in 2026, is one of 10 in phase 2, and was the 14th registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

2 of the 14 studies testing nivolumab in Rectal Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing nivolumab in Rectal Neoplasms, or all of them as a file.
02

Study summary

This is a small Phase II study testing whether targeted internal radiation treatment (HDREBT) followed by two doses of the immunotherapy drug Nivolumab is safe, practical, and potentially effective before patients undergo surgery (TME) to remove rectal cancer.

03

Conditions studied

  • Locally Advanced Rectal Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years at the time of consent.
  2. confirmed rectal adenocarcinoma arising within 5 to 15 cm of the anal verge as measured by sigmoidoscopy or MRI.
  3. Rectal cancer staging:

    1. Clinical Stage cT2 or cT3 based on high resolution pelvic MRI;
    2. No evidence of distant (cM0) on contrast -enhanced CT of chest, abdomen and pelvis (or PET/CT if clinically indicated);
    3. Disease deemed technically resectable with curative intent by multidisciplinary tumor board (MDT)*. No radiologic evidence of unresectable local disease (e.g., tumor fixation or invasion of adjacent unresectable structures).
  4. At least one of the following adverse prognostic features observed on baseline MRI:

    1. Node-positive disease (cN+);
    2. Threatened mesorectal fascia (MRF) defined as distance from tumor to mesorectal fascia \< 1mm on pelvic MRI;
    3. Extramural venous invasion (EMVI+).
  5. Proficient mismatch repair (pMMR) status, as determined by immunohistochemistry and/or microsatellite instability-low (MSI-L) status by next-generation sequencing
  6. Planned management includes therapy with radiotherapy followed by curative-intent TME.
  7. Prior external beam pelvic radiation for other (prostate, gynecology, lymphoma, bladder) are acceptable, provided the colorectal surgeon deems the patient as a candidate for TME surgery.
  8. performance status of 0-2
  9. Adequate organ function, defined by:

    1. (ANC) ≥ 1.5 x 109/L
    2. ≥ 100 x 109/L
    3. ≥ 90 g/L
    4. Estimated ≥ 30 mL/min
    5. Total ≤ 1.5 x (except for patients with Gilbert's syndrome who may only be included with total bilirubin ≤ 3.0 x ULN)
    6. (AST) ≤ 3.0 x ULN
    7. Alanine transaminase (ALT) ≤ 3.0 x ULN
    8. ≤ 1.5 ULN
    9. aPTT and PT ≤ 1.5 ULN
    10. Albumin ≥ 25 g/L
  10. Ability to understand, willing to provide written , and to comply with study requirements.

Exclusion criteria

Exclusion Criteria:

  1. Prior anticancer therapy for rectal cancer.
  2. to safe MRI imaging.
  3. Evidence of bowel obstruction on MRI or clinical evaluation.
  4. Evidence of distant .
  5. Medical or surgical contraindications to major pelvic surgery
  6. Active disease requiring systemic therapy.
  7. Active/uncontrolled infection. Infectious screening for , (HBV), (HBC) and tuberculosis will be performed at screening:

    1. Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received HBV anti-viral therapy for at least 4 weeks; and have undetectable HBV viral load prior to starting treatment. Participants should remain on anti-viral therapy throughout study intervention and follow local guidelines for HBV anti-viral therapy post completion of study intervention.
    2. Participants with a history of HCV infection are eligible if HCV viral load is undetectable at screening. Note: Participants must have completed curative anti-viral therapy at least 4 weeks prior to start of treatment.
    3. HIV-infected participants must have well-controlled HIV on antiretroviral treatment (ART), defined as:

    i. have a ≥ 0.35 x109 cells/L at the time of screening. ii. must have achieved and maintained virologic suppression defined as confirmed HIV ribonucleic acid (RNA) level below 50 or the LLOQ (below the limit of detection) using the locally available assay at the time of screening and for at least 12 weeks before screening.

    iii. must not have had any AIDS-defining opportunistic infections within the past 12 months.

    iv. must have been on a stable regimen, without changes in drugs or dose modification, for at least 4 weeks before start of treatment and agree to continue ART throughout the study.

  8. Known allergy or to nivolumab or any of its .
  9. Patients with other psychiatric, social or severe or uncontrolled medical conditions that in the opinion of the investigator may compromise their compliance with the protocol or may represent an unacceptable risk to their safety (e.g. uncontrolled diabetes, active or uncontrolled infection, uncontrolled cardiovascular disease).
  10. Requirement for prohibited concomitant medication, as outlined in section 8.4 within 14 days prior to first brachytherapy treatment.
  11. Treatment with other agents (defined as not used in accordance with the approved indication) within 28 days of first treatment.
  12. Patients who are pregnant or breastfeeding or not employing an effective method of .
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Brachytherapy (HDREBT) followed by nivolumab and total mesorectal excision

    HDREBT (26 Gy delivered in 4 fractions over Days 1-4) followed by up to 2 doses of nivolumab (3 mg/kg mg IV every 2 weeks starting at 7-14 days post HDREBT). Surgical resection of tumor (6-8 weeks post HDREBT)

    Drug: Nivolumab · Device: HDRBET · Procedure: Total Mesorectal Excision (TME)

Interventions

  • 2 doses of nivolumab 3 mg/kg mg IV every 2 weeks

  • DeviceHDRBET

    26 Gy in 4 fractions Administered over Days 1-4 as per institutional standard

  • ProcedureTotal Mesorectal Excision (TME)

    Targeted to take place 6-8 weeks post completion of HDREBT (maximum 12 weeks)

06

What researchers measure

Primary outcomes

  1. Pathologic complete response (pCR)

    Time frame: This is assessed at the time of total mesorectal excision surgery, occurring approximately 12 weeks after enrollment.

Secondary outcomes

  1. Incidence and severity of adverse events, as per CTCAE criteria v6.0

    Time frame: From time of first treatment through 90 days following last treatment with nivolumab

  2. Assess feasibility of treatment sequence

    Completion of treatment of all treatment modalities within protocol-defined timeframes (brachytherapy, immunotherapy and surgery)

    Time frame: This is assessed from the time of enrollment until the time of surgery, approximately 12 weeks after enrolment.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Vuong T, Devic S, Podgorsak E. High dose rate endorectal brachytherapy as a neoadjuvant treatment for patients with resectable rectal cancer. Clin Oncol (R Coll Radiol). 2007 Nov;19(9):701-5. doi: 10.1016/j.clon.2007.07.006. Epub 2007 Aug 22. PubMed 17714925 ↗
  • Lin ZY, Zhang P, Chi P, Xiao Y, Xu XM, Zhang AM, Qiu XF, Wu JX, Yuan Y, Wang ZN, Qu XJ, Li X, Nie X, Yang M, Cai KL, Zhang WK, Huang Y, Sun Z, Hou ZG, Ma C, Cheng FZ, Tao KX, Zhang T. Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial. Ann Oncol. 2024 Oct;35(10):882-891. doi: 10.1016/j.annonc.2024.06.015. Epub 2024 Jul 2. PubMed 38964714 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Dec 2028, 26 months after the start.

Of 229 non-industry phase 2 interventional studies under Rectal Neoplasms, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 80. This study's planned 26 months is below that.

Counting every sponsor, half of 243 studies reached it within 46 months; a quarter within 31 and three quarters within 75.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Oct 2026, on Oct 28, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2026
First posted
Jun 12, 2026
StartActual
Oct 22, 2026was Jul 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2030
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 28, 2026
Sites
Jewish General Hospital is now Recruiting
Oct 28, 2026
Start date
Jul 2026→Oct 2026
Oct 28, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Jewish General Hospital · Montreal, CanadaContact c•••@jgh.mcgill.ca→i•••@ssss.gouv.qc.ca
Oct 28, 2026
Show all 2 updates
  1. Nov 19, 2026
    Minor edits only
    + 2 other changes: verification date and date precision
  2. Oct 28, 2026
    Not yet recruiting→Recruiting
    Jewish General Hospital is now Recruiting
    Start date Jul 2026→Oct 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Jewish General Hospital · Montreal, CanadaContact c•••@jgh.mcgill.ca→i•••@ssss.gouv.qc.ca
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07645118
Lead sponsor
Dr. Te Vuong
Responsible party
Dr. Te Vuong (Professor Oncology, Radiation Oncologist, McGill University, Sir Mortimer B. Davis - Jewish General Hospital) — Sponsor-investigator
First posted
Jun 12, 2026
Start date
Oct 22, 2026
Primary completion
Dec 2028 (estimated)
Completion
Dec 2030 (estimated)
Last update
Nov 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion